NASDAQ:STML - Stemline Therapeutics Stock Price, Forecast & News

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

Stemline Therapeutics Inc (NASDAQ:STML) announced its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.42) by $0.08. The biopharmaceutical company had revenue of $13.33 million for the quarter, compared to analysts' expectations of $13.40 million. View Stemline Therapeutics' Earnings History.

Stemline Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Stemline Therapeutics.

Stemline Therapeutics updated its FY 2019 After-Hours earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $43.2-43.2 million, compared to the consensus revenue estimate of $46.44 million.

7 Wall Street analysts have issued 12-month target prices for Stemline Therapeutics' shares. Their forecasts range from $14.00 to $33.00. On average, they expect Stemline Therapeutics' stock price to reach $21.50 in the next year. This suggests a possible upside of 226.5% from the stock's current price. View Analyst Price Targets for Stemline Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stemline Therapeutics.

News articles about STML stock have been trending somewhat negative on Wednesday, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Stemline Therapeutics earned a news impact score of -1.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Stemline Therapeutics.

Some companies that are related to Stemline Therapeutics include TG Therapeutics (TGTX), Endo International (ENDP), Dicerna Pharmaceuticals (DRNA), Intra-Cellular Therapies (ITCI), Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), IGM Biosciences (IGMS), Madrigal Pharmaceuticals (MDGL), ZEALAND PHARMA/S (ZEAL), Myovant Sciences (MYOV), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Opko Health (OPK), Enanta Pharmaceuticals (ENTA) and Portola Pharmaceuticals (PTLA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Stemline Therapeutics investors own include TG Therapeutics (TGTX), Exelixis (EXEL), ZIOPHARM Oncology (ZIOP), Viking Therapeutics (VKTX), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), Fate Therapeutics (FATE), Immunomedics (IMMU), Catalyst Pharmaceuticals (CPRX) and Karyopharm Therapeutics (KPTI).

Stemline Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.52%), Empire Life Investments Inc. (1.14%) and California Public Employees Retirement System (0.17%). Company insiders that own Stemline Therapeutics stock include Alan S Forman, David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for Stemline Therapeutics.

STML stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Empire Life Investments Inc. and California Public Employees Retirement System. View Insider Buying and Selling for Stemline Therapeutics.

Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of STML stock can currently be purchased for approximately $6.59.

Stemline Therapeutics has a market capitalization of $330.10 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-85,020,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe.View Additional Information About Stemline Therapeutics.

The official website for Stemline Therapeutics is http://www.stemline.com/.

Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]